Clinical Trial Update: A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating TQB2450 in combination with Anlotinib for limited-stage small cell lung cancer; recruitment status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Small Cell Lung Cancer Limited Stage | Phase 3 | Status: NOT_YET_RECRUITING